Related Experiment Video
Updated: May 16, 2026

07:31
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
Jin-Ping Lai1, Avi Z Rosenberg, Markku M Miettinen
1Laboratory of Pathology; National Cancer Institute; NIH; Bethesda, MD USA.
Oncoimmunology
|December 18, 2012
Abstract:
NY-ESO-1 (CTAG 1B) is highly expressed in the majority of synovial sarcomas and myxoid/round cell liposarcomas as well as in a subset of melanomas, but only rarely in other mesenchymal tumors. This points to a potential for using NY-ESO-1 in the differential diagnosis of these lesions. Furthermore, promising results have been obtained in clinical trials testing NY-ESO-1-targeted immunotherapy in subsets of melanoma and synovial sarcoma patients.

